Attached files
file | filename |
---|---|
EX-10.1 - EX-10.1 - Cogent Biosciences, Inc. | d165110dex101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 16, 2021
COGENT BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-38443 | 46-5308248 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
200 Cambridge Park Drive, Suite 2500 Cambridge, Massachusetts |
02140 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (617) 945-5576
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which | ||
Common stock, $0.001 Par Value | COGT | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On Wednesday, June 16, 2021, Cogent Biosciences, Inc. (the Company) held its 2021 Annual Meeting of Stockholders (the 2021 Annual Meeting) at 9:00 a.m., Eastern Time. As of the close of business on April 26, 2021, the record date for the 2021 Annual Meeting, there were 38,410,267 shares of common stock entitled to vote at the meeting.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) At the 2021 Annual Meeting, the Companys stockholders approved an amendment to the Companys 2018 Stock Option and Incentive Plan (as so amended, the 2018 Plan) to increase the number of shares reserved for issuance thereunder by 6,000,000.
For additional information regarding the 2018 Plan, please refer to the heading Summary Description of the 2018 Plan contained in Proposal 2 of the Companys Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 30, 2021 (the Proxy Statement).
The foregoing description and the summary contained in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the 2018 Plan, which is filed as Exhibit 10.1.
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the 2021 Annual Meeting, each of the Companys director nominees was elected and each of the other proposals voted on was approved. The proposals are described in the Proxy Statement and the final voting results are set forth below.
Votes For |
Votes Withheld |
Broker Non-Votes |
||||||||||||
Proposal 1. Election of Directors |
||||||||||||||
Andrew Robbins |
26,197,715 | 15,545 | 6,594,309 | |||||||||||
Peter Harwin |
26,205,650 | 7,610 | 6,594,309 |
Votes For |
Votes Against |
Abstentions | Broker Non-Votes |
|||||||||||||
Proposal 2. Approval of Amendment to the 2018 Stock Option and Incentive Plan to Increase the Number of Authorized Shares |
19,927,003 | 6,236,714 | 49,543 | 6,594,309 | ||||||||||||
Proposal 3. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm |
32,800,873 | 1,881 | 4,815 | 0 | ||||||||||||
|
|
|
|
|
|
|
|
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Description | |
10.1 | Cogent Biosciences, Inc. Amended and Restated 2018 Stock Option and Incentive Plan, filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
COGENT BIOSCIENCES, INC. | ||||||
Date: June 17, 2021 | By: | /s/ John Green | ||||
John Green | ||||||
Chief Financial Officer |